Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 49: 983-986, 2003; 10.1373/49.6.983
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sebeková, K.
Right arrow Articles by Heidland, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sebeková, K.
Right arrow Articles by Heidland, A.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2003;49:983-986.)
© 2003 American Association for Clinical Chemistry, Inc.


Technical Briefs

Functional Hyperhomocysteinemia in Healthy Vegetarians: No Association with Advanced Glycation End Products, Markers of Protein Oxidation, or Lipid Peroxidation after Correction with Vitamin B12

Katarína Sebeková1,a, Marica Krajcovicová-Kudlácková1, Pavol Blazícek2, Vojtech Parrák3, Reinhard Schinzel4 and August Heidland4

1 Institute of Preventive and Clinical Medicine,
2 Hospital of Ministry of Defense of Slovak Republic, and
3 St. Cyril and Method Hospital, 833 01 Bratislava, Slovakia

4 University of Wuerzburg, 97070 Wuerzburg, Germany

aaddress correspondence to this author at: Institute of Preventive and Clinical Medicine, Limbová 14, 833 01 Bratislava, Slovakia; fax 421-2-59369-170, e-mail sebekova@upkm.sk

The first 300 words of the full text of this article appear below.

Vegetarians are at risk of developing hyperhomocysteinemia (HHcy). The predominant or selective consumption of proteins of plant origin shifts homocysteine (Hcy) metabolism to the remethylation pathway (1), which requires vitamin B12 as a cofactor and methyltetrahydrofolate as a substrate. In the vegetarian diet, the intake of folic acid exceeds the recommended dietary allowance (RDA), whereas intake of vitamin B12 is inadequate or even absent (2).

HHcy represents an independent risk factor for cardiovascular disease (3). Autooxidation of Hcy produces reactive oxygen species (ROS) (4), which may stimulate lipid peroxidation and formation of advanced oxidation protein products (AOPPs) and advanced glycation end products (AGEs). Interaction of AGEs with their specific receptor, RAGE, induces formation of ROS (5). In mice, HHcy was shown to enhance the expression of RAGE (6). AGEs, AOPPs, and lipid peroxidation products are implicated in the pathogenesis of degenerative and inflammatory diseases, including atherosclerosis (7).

In vegetarians, plasma concentrations of AGEs are mildly but significantly increased compared with populations on a Western mixed diet (8). We therefore investigated (a) whether there is an association between Hcy and plasma AGE concentrations or markers of protein oxidation and lipid peroxidation, and (b) whether supplementation of vitamin B12 affects the mentioned analytes in vegetarians with HHcy produced by a potential vitamin B12 deficit.

The study was approved by the Institutional Ethics Board and was conducted according to the Declaration of Helsinki. All participants gave written consent to participate.

We investigated 63 healthy vegetarians in whom HHcy had been revealed previously. The normohomocysteinemic (NHcy; Hcy <12.0 µmol/L) subgroup (with plasma folate and vitamin B12 concentrations within the appropriate reference intervals) was compared with the subgroup with functional HHcy (Hcy >12.0 µmol/L) attributable . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.